FANCM and cancer: The population of cancers targetable by EXO1 inactivation is likely an underestimation, as compound heterozygosity of loss-of-function mutations is observed in the majority of the 6.58% of all cancers mutated for FA core complex and FANCM complex factors (Table 1), which could be further increased through epigenetic silencing.